Senseonics, TypeZero and Roche Diabetes Care team-up to trial a long-term artificial pancreas system


Senseonics is teaming-up with TypeZero Technologies and Roche Diabetes Care to develop a long-term automated insulin delivery system. Part of the National Institutes of Health (NIH)-funded International Diabetes Closed Loop (IDCL) Trial, the collaboration was designed to test automated insulin delivery systems.

“This partnership is an example of how industry, research and clinical care work together to move innovative technologies from research to development and then to patients to minimize the burden of diabetes,” said Boris Kovatchev, PhD, Director of the Center for Diabetes Technology at the University of Virginia and principal investigator of the IDCL Trial.

This phase of the IDCL Trial will integrate Senseonics’ Eversense CGM System, a long-term, implantable continuous glucose monitoring (CGM) system with TypeZero’s inControl AP algorithms and Roche’s Accu-Chek Insight Insulin Pump. The inControl software will automatically adjust and regulate insulin delivery based on the combination of data received from the CGM system and the insulin pump.

The trial will include three clinical centers in Europe — the University of Amsterdam in the Netherlands, the University of Padova in Italy and University Hospital of Montpellier in France.

“The promise of automated insulin delivery systems is the ability to automatically and sustainably maintain tight glucose control while avoiding hypoglycemia,” said Tim Goodnow, President and CEO of Senseonics. “With this partnership, we are one step closer to bringing this promise to market and to significantly improve the everyday challenges of people with diabetes.”

No dates were provided in the press release, but we will be on the lookout for additional information as soon as they’re released. Stay tuned…